Alastal Yaseen, Hammad Tariq A, Renno Anas, Khalil Basmah, Pierre Joel, Kwaah Bismark, Khuder Sadik A, Nawras Ali
Department of Internal Medicine, Division of Gastroenterology (Yaseen Alastal, Tariq A. Hammad, Anas Renno, Basmah Khalil, Ali Nawras), University of Toledo, Toledo, OH, USA.
Department of Public Health and Preventive Medicine (Joel Pierre, Bismark Kwaah, Sadik A. Khuder), University of Toledo, Toledo, OH, USA.
Ann Gastroenterol. 2017;30(5):498-503. doi: 10.20524/aog.2017.0171. Epub 2017 Jun 30.
Systemic sclerosis (SSc) is a multisystem disease associated with significant morbidity and increased mortality. The prevalence of different gastrointestinal (GI) manifestations has been investigated in multiple, but mainly small, retrospective studies. In this study, we investigated the prevalence and risk for a broad spectrum of GI disorders and malignancies in a large sample of inpatients with SSc in the United States.
We conducted a retrospective analysis using the 2010-2011 Healthcare Cost and Utilization Project - Nationwide Inpatient Sample (HCUP-NIS). SSc patients were identified by ICD-9-CM code 710.1. Non-SSc patients ("controls") were matched to cases 4:1 by age and sex. We examined demographics, clinical characteristics, and a range of GI conditions.
From 15,824,031 total patients, 13,633 cases of SSc were matched to 54,532 controls. The prevalence of GI manifestations among SSc patients was 59.24% compared to 29.96% for controls (P<0.0001). Significantly elevated GI manifestations in SSc patients included dysphagia (4.3% vs. 1.9%, P<0.0001), esophageal reflux (34.8% vs. 15.4%, P<0.0001), Barrett's esophagus (1.7% vs. 0.3%, P<0.0001), constipation (6% vs. 4.6%, P<0.0001), diarrhea (4.5% vs. 2.4%, P<0.0001), fecal incontinence (0.4% vs. 0.2%, P<0.0001), and celiac disease (0.2% vs. 0%, P<0.0001). Some GI disorders were significantly lower in SSc patients, including cholelithiasis (1.6% vs. 2.1%, P<0.0001) and GI malignancies (1% vs. 2.2%, P<0.0001).
Our results emphasize the established association between SSc and esophageal disorders, such as dysphagia and reflux disease. Our analysis indicated a significant positive association between SSc and celiac disease, and a negative association between SSC and cholelithiasis.
系统性硬化症(SSc)是一种多系统疾病,与显著的发病率和死亡率增加相关。多种不同的胃肠道(GI)表现的患病率已在多个(但主要是小型的)回顾性研究中进行了调查。在本研究中,我们调查了美国大量住院SSc患者中广泛的胃肠道疾病和恶性肿瘤的患病率及风险。
我们使用2010 - 2011年医疗保健成本与利用项目 - 全国住院患者样本(HCUP - NIS)进行了回顾性分析。通过ICD - 9 - CM编码710.1识别SSc患者。非SSc患者(“对照”)按年龄和性别以4:1的比例与病例匹配。我们检查了人口统计学、临床特征以及一系列胃肠道疾病情况。
在总共15,824,031例患者中,13,633例SSc病例与54,532例对照匹配。SSc患者中胃肠道表现的患病率为59.24%,而对照为29.96%(P < 0.0001)。SSc患者中显著升高的胃肠道表现包括吞咽困难(4.3%对1.9%,P < 0.0001)、食管反流(34.8%对15.4%,P < 0.0001)、巴雷特食管(1.7%对0.3%,P < 0.0001)、便秘(6%对4.6%,P < 0.0001)、腹泻(4.5%对2.4%,P < 0.0001)、大便失禁(0.4%对0.2%,P < 0.0001)和乳糜泻(0.2%对0%,P < 0.0001)。一些胃肠道疾病在SSc患者中显著较低,包括胆结石(1.6%对2.1%,P < 0.0001)和胃肠道恶性肿瘤(1%对2.2%,P < 0.0001)。
我们的结果强调了SSc与食管疾病(如吞咽困难和反流性疾病)之间已确立的关联。我们的分析表明SSc与乳糜泻之间存在显著正相关,与胆结石之间存在负相关。